Invitrogen, which supplies reagents, services and software for the
life science market, has continued its acquisitive streak with the
announcement that it is paying $35 million (€27.5m) for a UK firm -
DNA Research Innovations - specialising...
Invitrogen, a provider of life science technologies, has entered
into new licensing agreements to supply its Gateway Technology and
clones to worldwide genomic research centres. This will allow
scientists and laboratories to share...
Dutch biotech firm Qiagen has announced the acquisition of key
assets of Molecular Staging (MSI), which includes the Whole Genome
Amplification (WGA) technology, designed to eliminate limitations
created by scarce quantities of DNA...
Representatives of the pharmaceutical and biotechnology industries
presented strong opposition to the concept of biogenerics at a
recent meeting convened by the US Food and Drug Administration. As
expected, their argument centred...
Italy's Marchesini has introduced a new packaging system that can
handle safety syringes, which are underused in Europe compared to
the US despite their proven benefits in reducing needlestick
injuries, reports Phil Taylor. It...
The European Union is sponsoring a new initiative aimed at
producing pharmaceuticals in genetically modified crop plants such
as maize, and hopes to start the first clinical trials of a product
by 2009. But the news has been met with...
The company Evotec OAI, a drug discovery and development solution
provider to the pharmaceutical and biotechnology industries has
announced the successful expansion of their in vitro and in silico
ADMET (Adsorption, Distribution,...
The impact on the French chemicals industry of implementing the
European Union's REACH (Registration, Evaluation and Authorisation
of Chemicals) proposals could be as high €800 million in testing
alone and lead to the loss of...
Researchers in Finland and the US have identified a gene that
predisposes people to one of the most common causes of coronary
heart disease, raising the hope that it could represent a new
target for drug treatment.
Earlier this week, the US Food and Drug Administration suspended
the approval of a generic version of Pfizer's high blood pressure
drug Norvasc (amlodipine besylate) developed by India's Dr Reddy's
Novartis' generic drugs subsidiary Sandoz has opened two new
manufacturing plants in Austria and Slovenia that mark its entry
into the contract manufacture of biopharmaceuticals using mammalian
US chemicals firm Aceto has bought the German Pharma Waldhof
business from Switzerland's Roche, making its first foray into the
market for biologically-derived active pharmaceutical ingredients
The new agreement between BioProgress and an unnamed US
over-the-counter pharmaceuticals firm could double the UK company's
capacity to manufacture cellulose films for drug encapsulation,
according to chief executive Graham Hind.
Funding shortfalls and a capacity gap are threatening to hamper the
European biopharmaceutical industry's progress and could lead to a
reduction in its global market share, according to new market
Merck KGaA drops plans to build a €300m biomanufacturing plant in
Jena, Germany, on the grounds that late-stage product failures have
left plenty of free capacity in the contract sector. The company's
move suggests that the often-repeated...
The recently-formed Advanced Biosciences unit of Rohm and Haas has
introduced the first product in a new line of functionalised resin
systems for the immobilisation of biocatalytic enzymes at the CphI
meeting in Frankfurt, Germany.
A team of researchers at Switzerland's Novartis and Rigel
Pharmaceuticals in the USA have created a method for discovering
molecules that are involved in signalling pathways, according to a
report in the Journal of Biology.
The genomics industry is already separating into two tiers; the
winners are those focused on targets and drug development and which
have products in or near the clinic, as well as strong
partnerships, says analyst
KS Avicenna, the Canadian unit of KS Biomedix of the UK, launched a
newly expanded contract biopharmaceutical manufacturing facility in
Canada, to service both North American and European clients, at the
start of the BIO 2003 meeting,...